| 產品名稱 |
Human rhinovirus 9 |
| 商品貨號 |
B231323 |
| Classification |
Picornaviridae, Rhinovirus |
| Agent |
Human rhinovirus 9 |
| Strain |
211 [211-CV 13] |
| Applications |
Respiratory research |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Isolation |
This product is a mycoplasma free preparation derived from ATCC VR-489. |
| Product Format |
frozen |
| Storage Conditions |
Store at ?-70°C or colder |
| Comments |
This product is a mycoplasma free preparation derived from ATCC VR-489. |
| Effect on Host |
Typical rhinovirus CPE in cell culture, including rounding and sloughing of infected cells. |
| Growth Medium |
ATCC® Medium 30-2003: Eagle's Minimum Essential Medium (EMEM)
Fetal Bovine Serum
|
| Recommended Host |
Production Host:H1-HeLa (ATCC CRL-1958) Recommended Host: ?H1HeLa (ATCC? CRL-1958™) Alternate Hosts:HeLa (ATCC CCL-2), WI-38 (ATCC CCL-75), MRC-5 (ATCC CCL-171) |
| Growth Conditions |
Plant cells 24 hours in advance and infect when cultures are 80-90% confluent. Remove medium and inoculate with a small volume of virus diluted with VGM to provide a MOI of about 0.1. Adsorb 1 hour at 33.0°C in a humidified, 5% CO2 atmosphere with continuous rocking. End adsorption by adding virus growth medium. Incubate at 33.0°C in a humidified, 5% CO2 atmosphere for 3-7 days with rocking, until CPE are well advanced in 100% of the culture. |
| Name of Depositor |
VV Hamparian, RM Conant |
| Source |
Presumed from human throat washings; derived from ATCC VR-489 following treatment to remove mycoplasma contamination. |
